MDB Capital Holdings, LLC (MDBH)

NCM – Цена в реальном времени. Валюта: USD

3.89

+0.20 (5.29%)

При закрытии: May 12, 2026, 4:00 PM EDT

08.05.2026

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

� Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms.

29.04.2026

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse: “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.”

01.04.2026

MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript

31.03.2026

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse report, “The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine.”

30.03.2026

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced a new addition to its IP Legal Insights section on the company website, a platform dedicated to sharing expert legal perspectives on intellectual property strategy, emerging technology, and innovation-driven industries.

23.03.2026

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time

Addison, TX, March 23, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing the results will be issued prior to the call.

11.03.2026

PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

Dallas, TX, March 11, 2026 (GLOBE NEWSWIRE) -- PatentVest announced the completion of a strategic intellectual property engagement with Porosome Therapeutics, Inc., a biotechnology company developing a first-in-class therapeutic platform designed to restore cellular secretion mechanisms.

Видео

No Data

There is no data to display

Пресс-релизы

08.05.2026

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

� Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms.

29.04.2026

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

31.03.2026

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

30.03.2026

MDB Capital Holdings, LLC (MDBH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

MDB Capital Holdings, LLC (MDBH)

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time

PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

Видео

No Data

Пресс-релизы

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time

PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

Видео

No Data

Пресс-релизы

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

Search stocks

MDB Capital Holdings, LLC (MDBH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

MDB Capital Holdings, LLC (MDBH)

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time

PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

Видео

No Data

Пресс-релизы

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time

PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

Видео

No Data

Пресс-релизы

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork